Tumor volume changes during and after temozolomide treatment for newly diagnosed higher-grade glioma (III and IV).

Tumor volume changes during and after temozolomide treatment for newly diagnosed higher-grade glioma (III and IV).

World Neurosurg. 2018 Mar 16;:

Authors: Wang HC, Lin YT, Lin WC, Ho RW, Lin YJ, Tsai NW, Ho JT, Lu CH

Abstract
BACKGROUND: A standard post-concomitant radiochemotherapy involving adjuvant temozolomide (TMZ) was stopped after 6 cycles for high-grade gliomas (HGG). Several studies demonstrated that prolonged TMZ treatment increased survival for these patients.
METHODS: This retrospective study aimed to compare changes in tumor volume during and after adjuvant TMZ treatment and overall survival (OS).
RESULTS: There were 90 patients were administered adjuvant TMZ treatment. Comparing average tumor volume changes during TMZ treatment and after TMZ was stopped, a significant decrease in tumor volume was observed during TMZ treatment in the total patient population, the AA group, and the GBM group (P ≤ .001, P = .042, and P = .005, respectively). Median OS was 78.4 weeks and was significant regarding the surgical tumor resection rate (r = 0.241; P = .04) and total TMZ treatment cycles (r = 0.631, P ≤ .001).
CONCLUSIONS: During adjuvant TMZ treatment, tumor volume significantly decreased in patients with GBM and AA. Prolonged TMZ administration improved OS, without increased toxicity.

PMID: 29555610 [PubMed - as supplied by publisher]

http://ift.tt/2DJIIil